Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader population.The regulatory body approved the drug as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled CRSwNP.The latest approval expands the initial FDA approval (granted in June 2019) in CRSwNP for patients aged 18 years and older.Regeneron’s shares have ra ...